

MICHIGAN DEPARTMENT OF ENVIRONMENT, GREAT LAKES, AND ENERGY

INTEROFFICE COMMUNICATION

TO: File for Ethyl *tertiary* butyl ether (CAS# 637-92-3)

FROM: Doreen Lehner, Toxics Unit, Air Quality Division

DATE: June 5, 2024


SUBJECT: Screening Level for Ethyl *tertiary* butyl ether (CAS# 637-92-3)

Summary

The initial risk screening level (IRSL) for ethyl *tertiary* butyl ether is 10 µg/m³ (annual averaging time) and the secondary screening level (SRSL) is 100 µg/m³ (annual averaging time). **This document is updated to fix calculation errors that occurred in the derivation of the original justification dated November 28, 2023.**

Uses and Physical Chemical Properties

Ethyl *tertiary* butyl ether is used as an oxygenate gasoline additive to improve combustion efficiency and reduce pollutants in exhaust. "Ethyl *tertiary* butyl ether is released into the environment through gasoline leaks, evaporation, spills and other releases" (EPA, 2021).

| Table 1. Physical/Chemical Properties of 1,1-Dichloroethylene | |
|---|---|
| Structure |  |
| CAS Number | 637-92-3 |
| Synonyms | Ethyl <i>t</i> -butyl ether; 2-ethoxy-2-methylpropane; ethyl <i>tert</i> -butyl ether; 2-methyl-2-ethoxypropane; ETBE |
| Appearance/Odor | Clear, light-yellow liquid with a strong, highly objectionable terpene-like odor and extremely flammable |
| Molecular Weight | 102.177 g/mol |
| Melting Point | -94°C |

| | |
|---------------------------------|--|
| Boiling Point | 72.4°C |
| Flash Point | -19°C (closed cup) |
| Autoignition Temperature | 375 °C |
| Solubility: Water | 1.2 x 10 ⁺⁴ mg/L @ 20°C |
| Density | 0.7364 g/cm ³ @ 25°C |
| Vapor Pressure | 124 mm Hg at 25°C |
| Henry's Law Constant | 1.64 x 10 ⁻³ atm-m ³ /mole at 25°C |

Literature Search

The literature was searched to find relevant data to assess the toxicity of ethyl *tertiary* butyl ether. The following references or databases were searched: U.S. Environmental Protection Agency (EPA) Integrated Risk Information System (IRIS), Registry for Toxic Effects of Chemical Substances (RTECS), American Conference of Governmental and Industrial Hygienists (ACGIH) Threshold Limit Values (TLVs), National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Levels (RELs), International Agency for Research on Cancer (IARC) Monographs, Chemical Abstract Service (CAS) SciFinder (searched 6/2/2023), U.S. EPA ChemView, California Office of Environmental Health Hazard Assessment (OEHHA), the U.S. Department of Health and Human Services Agency for Toxic Substances and Disease Registry (ATSDR), European Chemical Agency (ECHA), and the U.S. National Toxicology Program (NTP).

Key Study

The IRSL was based on the EPA IRIS inhalation unit risk (IUR) of 8 x 10⁻⁵ per mg/m³. EPA Cancer Guidelines (EPA, 2005) state, “the evidence of carcinogenic potential for ETBE is *suggestive* for inhalation exposure but *inadequate* for oral exposure. ETBE induced liver tumors in male (but not female) rats in a 2-year inhalation exposure study (Saito et al., 2013; JPEC 2010)” (EPA, 2021). “In F344 rats, administration of ETBE via inhalation increased hepatocellular adenomas in males in an exposure-dependent manner, as indicated by a significant positive trend ($p < 0.001$ with Peto’s test). Hepatocellular tumors were not increased in female rats (Saito et al., 2013). A significantly increased incidence of hepatocellular adenomas or carcinomas (only one carcinoma observed) was observed at the highest dose tested in males, and three hepatocellular adenomas were observed at the two lower concentrations. Significant increases in preneoplastic foci (basophilic and eosinophilic foci) were also observed in male rats (Saito et al., 2013)” (EPA, 2021).

“A quantitative estimate of carcinogenic potential from inhalation exposure to ETBE was based on the increased incidence of hepatocellular adenomas and carcinomas in male F344 rats following 2-year inhalation exposure (Saito et al., 2013; JPEC 2010). The study included histological examinations for tumors in many different tissues, contained three exposure levels and controls, contained adequate numbers of animals per dose

group (~50/sex/group), treated the animals for up to 2 years, and included detailed reporting of methods and results” (EPA, 2021).

“...[S]upplementary evidence from two-stage initiation-promotion oral carcinogenesis bioassays indicate increased mutagen-initiated liver tumors, as well as increased tumor incidence in the thyroid, colon, and urinary bladder” (EPA, 2021).

There are also susceptible populations that may be more affected by exposure to ethyl *tertiary* butyl ether. “ETBE is metabolized to *tert*-butanol and acetaldehyde. Evidence is suggestive that genetic polymorphism of aldehyde dehydrogenase (ALDH) – the enzyme that oxidizes acetaldehyde to acetic acid – could affect ETBE toxicity. The virtually inactive form, ALDH2*2, is found in about one-half of all East Asians [and by extension people of East Asian ancestry; Brennan et al. (2004)]. Evidence is strong in humans that this ALDH2 variant increases the internal dose of acetaldehyde and the cancer risks from acetaldehyde, especially in the development of ethanol-related cancers (Eriksson, 2015; IARC, 2010). Several in vivo and in vitro genotoxicity assays in Aldh2 knockout (KO) and heterozygous mice reported that genotoxicity was significantly increased compared with wild-type controls following ETBE exposure to similar doses associated with cancer and noncancer effects in rodents (Weng et al., 2019; Weng et al., 2014; Weng et al., 2013; Weng et al., 2012; Weng et al., 2011). Inhalation ETBE exposure increased blood concentrations of acetaldehyde in Aldh2 KO mice compared with wild type (Weng et al., 2013). Thus, exposure to ETBE in individuals with the ALDH2*2 variant would be expected to increase the internal dose of acetaldehyde and potentially increase risks associated with acetaldehyde produced by ETBE metabolism in the liver. Collectively, these data present evidence that people with diminished ALDH2 activity could be considered a susceptible population that could be more sensitive to liver toxicity from ETBE exposure” (EPA, 2021).

“The available evidence base for the nuclear hormone receptor MOAs (i.e., peroxisome proliferator-activated receptor α [PPAR α], pregnane X receptor [PXR], and the constitutive androstane receptor [CAR]) was inadequate to determine the role these pathways play, if any in ETBE-induced liver carcinogenesis” (EPA, 2021).

IRSL Derivation

“An inhalation unit risk was derived for liver tumors in male F344 rats. The modeled ETBE POD was scaled to an HEC according to EPA guidance based on inhalation dosimetry for a Category 3 gas (EPA, 1994). Using linear extrapolation from the benchmark concentration lower confidence level corresponding to 10% extra risk (BMCL₁₀), a human equivalent inhalation unit risk was derived using inhalation unit risk = 0.1/BMCL₁₀ and calculated to be 8×10^{-5} mg/m³” (EPA, 2021).

Rule 231(1) was used to develop the IRSL using the following equation:

$$IRSL = \frac{1 \times 10^{-6}}{Unit\ Risk}$$

Where:

Unit Risk = Additional lifetime cancer risk occurring in a population in which all individuals are exposed continuously for life to a concentration of 1 microgram per cubic meter of the chemical in the air.

The EPA IUR of 8×10^{-5} per mg/m³ is converted to an IUR of per µg/m³ using the following equation:

$$IUR = \frac{8 \times 10^{-5} \text{ m}^3}{\text{mg}} \times \frac{1 \text{ mg}}{1000 \text{ } \mu\text{g}} = 8 \times 10^{-8} \text{ m}^3/\mu\text{g}$$

Using the EPA IUR value above in the IRSL equation:

$$IRSL = \frac{0.000001}{0.00000008 (\mu\text{g}/\text{m}^3)^{-1}} = 12.5 \text{ } \mu\text{g}/\text{m}^3 \approx 10 \text{ } \mu\text{g}/\text{m}^3$$

According to Rule 231(3) the averaging time for an IRSL or SRSL is annual. Therefore, the IRSL for ethyl *tertiary* butyl ether is 10 µg/m³ with an annual averaging time and the SRSL is 100 µg/m³ with an annual averaging time.

References

Act 451 of 1994, Natural Resources and Environmental Protection Act and Air Pollution Control Rules, Michigan Department of Environment, Great Lakes, and Energy.

Brennan P, Lewis S, Hashibe M, Bell DA, Boffetta P, Bouchardy C, Caporaso N, Chen C, Coutelle C, Diehl SR, Hayes RB, Olshan AF, Schwartz SM, Sturgis EM, Wei Q, Zavras AI, and Benhamou S. 2004. Pooled analysis of alcohol dehydrogenase genotypes and head and neck cancer: a HuGE review. American Journal of Epidemiology 159(1): 1-16. Available online at: [Pooled Analysis of Alcohol Dehydrogenase Genotypes and Head and Neck Cancer: A HuGE Review | American Journal of Epidemiology | Oxford Academic \(oup.com\)](#)

EPA. 1994. Methods for Derivation of Inhalation Reference Concentrations (RfCs) and Application of Inhalation Dosimetry. U.S. Environmental Protection Agency, Office of Research and Development, Office of Health and Environmental Assessment, Washington, DC. EPA/600/8-90/066F. Available online at: [Methods For Derivation Of Inhalation Reference Concentrations \(RfCs\) And Application Of Inhalation Dosimetry | Risk Assessment Portal | US EPA](#)

EPA. 2021. Toxicological Review of Ethyl Tertiary Butyl Ether (CASRN 637-92-3). Integrated Risk Information System, Center for Public Health and Environmental Assessment, Office of Research and Development, U.S. Environmental Protection

Agency, Washington, DC. EPA/635/R-20/400Fa. Available online at: [Ethyl Tertiary Butyl Ether \(ETBE\) CASRN 637-92-3 | IRIS | US EPA, ORD](#)

Eriksson CJ. 2015. Genetic-epidemiological evidence for the role of acetaldehyde in cancers related to alcohol drinking. *Advances in Experimental Medicine and Biology* 815:41-58.

IARC. 2010. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 96. Alcohol Consumption and Ethyl Carbamate. World Health Organization International Agency for Research on Cancer. Available online at: [IARC Publications Website - Alcohol Consumption and Ethyl Carbamate](#)

JPEC. 2021. Carcinogenicity test of 2-Ethoxy-2-methylpropane in rats (Inhalation study). Japan Petroleum Energy Center, Japan Industrial Safety and Health Association. Study No: 0686.

Saito A, Sasake T, Kasai T, Katagiri T, Nishizawa T, Noguchi T, Aiso S, Nagano K, and Fukushima S. 2013. Hepatotumorigenicity of ethyl tertiary-butyl ether with 2-year inhalation exposure in F344 rats. *Archives of Toxicology* 87(5): 905-914.

Weng ZQ, Suda M, Ohtani K, Mei N, Kawamoto T, Nakajima T, and Wang RS. 2011. Aldh2 Knockout Mice were more Sensitive to DNA Damage in Leukocytes due to Ethyl Tertiary Butyl Ether Exposure. *Industrial Health* 49(3):396-399. Available online at: [Aldh2 knockout mice were more sensitive to DNA damage in leukocytes due to ethyl tertiary butyl ether exposure - PubMed \(nih.gov\)](#)

Weng Z, Suda M, Ohtani K, Mei N, Kawamoto T, Nakajima T, and Wang R. 2012. Differential genotoxic effects of subchronic exposure to ethyl tertiary butyl ether in the livers of Aldh2 knockout and wild-type mice. *Archives of Toxicology* 86(4):675-582.

Weng Z, Suda M, Ohtani K, Mei N, Kawamoto T, Nakajima T, and Wang R. 2013. Subchronic exposure to ethyl tertiary butyl ether resulting in genetic damage in Aldh2 knockout mice. *Toxicology* 311(3):107-114.

Weng Z, Ohtani K, Suda M, Yanagiba Y, Kawamoto T, Nakajima T, and Wang RS. 2014. Assessment of the reproductive toxicity of inhalation exposure to ethyl tertiary butyl ether in male mice with normal, low active and inactive ALDH2. *Archives of Toxicology* 88(4):1007-1021.

Weng Z, Shi Y, Suda M, Yanagiba Y, Kawamoto T, Nakajima T, and Wang R. 2019. Inhalation exposure to low levels of ethyl tertiary butyl ether: Its genetic effects were significantly modified by ALDH2 activity. *Environmental and Molecular Mutagenesis* 60(2):145-153.

DL:lh